![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 13, Issue 6, 1929-1939, June 2002


§


**
Departments of *Biochemistry,
Surgery,
¶Pathology, and @Genetics, and
Howard Hughes Medical Institute, Stanford University
School of Medicine, Stanford, California 94305; #Department
of Surgery, Beijing Cancer Hospital, Beijing, China; and Departments of
§Surgery and §§Pathology, The University of
Hong Kong, Hong Kong, China
| |
ABSTRACT |
|---|
|
|
|---|
Hepatocellular carcinoma (HCC) is a leading cause of death worldwide. Using cDNA microarrays to characterize patterns of gene expression in HCC, we found consistent differences between the expression patterns in HCC compared with those seen in nontumor liver tissues. The expression patterns in HCC were also readily distinguished from those associated with tumors metastatic to liver. The global gene expression patterns intrinsic to each tumor were sufficiently distinctive that multiple tumor nodules from the same patient could usually be recognized and distinguished from all the others in the large sample set on the basis of their gene expression patterns alone. The distinctive gene expression patterns are characteristic of the tumors and not the patient; the expression programs seen in clonally independent tumor nodules in the same patient were no more similar than those in tumors from different patients. Moreover, clonally related tumor masses that showed distinct expression profiles were also distinguished by genotypic differences. Some features of the gene expression patterns were associated with specific phenotypic and genotypic characteristics of the tumors, including growth rate, vascular invasion, and p53 overexpression.
| |
INTRODUCTION |
|---|
|
|
|---|
Hepatocellular carcinoma (HCC) is the most common liver malignancy
and among the five leading causes of cancer death in the world.
Virtually all HCCs are associated with chronic hepatitis B virus (HBV)
or hepatitis C virus infections (Beasley, 1988
; Hasan et
al., 1990
), but the molecular nature of this association is poorly
understood. HCC treatment options remain limited. Surgical resection is
considered the only "curative treatment" (Lin et al.,
1987
), but >80% of patients have widespread HCC at the time of
diagnosis and are not candidates for surgical treatment. Among patients
with localized HCC who undergo surgery, 50% suffer a recurrence (Okuda
et al., 1984
). Standard clinical pathological classification
of HCC has limited value in predicting the outcome of treatment.
Clearly, molecular markers for early and accurate diagnosis and
classification of HCC would address an important medical need.
The phenotypic diversity of cancer is accompanied by a corresponding
diversity in gene expression patterns (Perou et al., 1999
;
Alizadeh et al., 2000
; Perou et al., 2000
; Ross
et al., 2000
; Welsh et al., 2001
). Herein, we
describe a systematic characterization of gene expression patterns in
human liver cancers. We used cDNA microarrays containing 23,000 clones,
representing ~17,400 human genes, to study tumor and nontumor liver
tissues from HCC patients. Our aim was to characterize the gene
expression programs associated with HCC as a step toward a better
understanding of the molecular pathophysiology, and better methods for
detection, diagnosis, and classification of HCC.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Tissues and RNA Isolation
All patients participating in this study gave informed consent
before surgery. All tissues were surgically resected, snap frozen in
liquid nitrogen within 0.5 h after the resection, and stored at
80°C. In most cases, both tumor and adjacent nontumor tissues were
collected. A portion of each specimen, ~0.5-1
cm3, was sampled. Each sample was dissected into
three equal slices. One was used for RNA extraction, one for genomic
DNA iolsation, and the other processed for histological examination.
Each histological slide was independently reviewed by two pathologists.
Total RNA was extracted with RNeasy kit (QIAGEN, Valenica, CA), and
mRNA was isolated from total RNA by using FastTrack (Invitrogen,
Carlsbad, CA) or Poly-(A)Pure (Ambion, Austin, TX) mRNA purification
kit. mRNA from cell lines was purified directly with FastTrack
(Invitrogen) kit. We combined mRNA from the following cells, in equal
quantities, to make the reference pool: HepG2, SNU398, SNU1, Jurkat,
RPMI, and CCD-1070SK.
Microarray Procedure
cDNA clones (23,075), representing ~17,400 genes, were
mechanically printed onto treated glass microscope slides, as described previously (Perou et al., 2000
)
(http://cmgm.stanford.edu/pbrown/array.html). Approximately 18,700 of
the clones were obtained from Research Genetics, and 4,300 clones were
obtained directly from Cancer Genome Anatomy Project
(http://www.ncbi.nlm.nih.gov/ncicgap/). The hybridizations were
performed as described previously (Alizadeh et al., 2000
). A
detailed protocol is available at
http://cmgm.stanford.edu/pbrown/protocols/5_hyb_human.html. In
brief, 2 µg of sample mRNA and 2 µg of reference mRNA were labeled
with Cy5-dUTP and Cy3-dUTP (Amersham Biosciences, Piscataway, NJ),
respectively, by using Reverse Transcriptase (Invitrogen) for
2 h at 42°C. The two labeled cDNA probes were separated from unincorporated nucleotides by filtration, mixed, and hybridized to
microarray at 65°C overnight. After hybridization, each microarray was washed with 2× SSC, 0.03%SDS for 5 min at 65°C then with 1× SSC for 5 min and 0.1× SSC for 5 min, both at room temperature. The
array was then scanned using GenePix 4000A microarray scanner (Axon
Instruments, Union City, CA). Array CGH was performed as described previously (Pollack et al., 1999
). The
detailed protocol is available at
http://cmgm.stanford.edu/pbrown/protocols/4_genomic.html.
Data Analysis
Primary data collection and analysis were carried out using
GenePix Pro 3.0 (Axon Instruments). Areas of the array with obvious blemishes were manually flagged and excluded from subsequent analysis. The raw data were deposited into Stanford Microarray Database (Sherlock
et al., 2001
) at
http://genome-www4.stanford.edu/MicroArray/SMD/index.html. All
nonflagged array elements for which the fluorescent intensity in each
channel was >1.5 times the local background were considered well
measured. Genes for which <75% of measurements across all the samples
in this study met this standard were excluded from further analysis. We
selected for further analysis genes whose expression level differed by
at least threefold, in at least four samples, from their mean
expression level across all samples. We applied a hierarchical
clustering algorithm both to the genes and arrays by using the Pearson
r as the measure of similarity, and average linkage clustering, as
described previously (Eisen et al., 1998
). The results were
visualized and analyzed with TreeView (M. Eisen; http://rana.lbl.gov).
We used two-sample Welch t statistics (allowing for unequal
variances) to identify genes that were differentially expressed in two
sets of samples. The statistical significance of the differential
expression of any gene was assessed by computing a p value for each
gene, representing the chance of observing a test statistic at least as
large (in absolute value) as the value actually obtained. No specific
parametric form was assumed for the distribution of the test
statistics. To determine the p value, we used a permutation procedure
in which the class labels of the samples were permuted 500,000 times,
and for each permutation, two-sample t statistics were
computed for each gene. The permutation p value for a particular gene
is the proportion of the permutations (out of 500,000) in which the
permuted test statistic exceeds the observed test statistic in absolute
values. Any gene for which this p value was <0.001 was considered to
be differentially expressed. The corresponding "per-family type 1 error rate" (PFER), that is, the expected number of false positives
for such a multiple test procedure is PFER = number of genes × 0.001. Alternatively, the Benjamin & Hochberg procedure was applied
to control the "false discovery rate" (FDR), or expected proportion
of false positive among the genes declared differentially expressed.
Immunohistochemistry
Immunohistochemistry was performed as described previously
(Perou et al., 1999
). Antibody MY10, for CD34, was used at
1:10 dilution (BD Biosciences, San Jose, CA). Antibody DO-7, for p53, was used at 1:100 dilution (DAKO, Carpinteria, CA).
Southern Analysis
Genomic DNA was extracted using the DNeasy extraction kit (QIAGEN), digested overnight with HindIII or EcoRI, and resolved by electrophoresis through a 1% agarose gel. After depurination, denaturation, and neutralization, the gel was transferred overnight with 10× SSC to a nylon Hybond-N+ membrane (Applied Biosystems, Foster City, CA). HBV-specific sequences were detected by hybridization with a polymerase chain reaction-amplified copy of the complete HBV genome, from blood of a patient with HBV infection, labeled with fluorescein by random primed labeling (Applied Biosystems). Detection was performed with anti-fluorescein antibody conjugated with horseradish peroxidase, followed with enhanced chemiluminescence development (Applied Biosciences) and exposure to x-ray film (Eastman Kodak, Rochester, NY).
| |
RESULTS |
|---|
|
|
|---|
Gene Expression in HCC and Nontumor Liver Tissues
We characterized genomic expression patterns in >200 samples, including 102 primary HCC (from 82 patients), 74 nontumor liver tissues (from 72 patients), seven benign liver tumor samples (three adenoma and four FNH), 10 metastatic cancers, and 10 HCC cell lines. The complete data are available at http://genome-www.stanford.edu/hcc/Figures/ArrayInformation.htm.
As a first step to organize the results for visual display and for
further analysis, we used a hierarchical clustering algorithm (Eisen
et al., 1998
) to group the genes, as well as the samples, on
the basis of similarity in their expression pattern. The results for
the 3180 genes (represented by 3964 cDNAs) with the greatest variations
in expression in 82 HCC and 74 nontumor liver tissues samples are
displayed in Figure 1. To help provide a
framework for interpretation of the expression patterns observed in the clinical samples, we compared these results with the gene expression patterns in 10 HCC cell lines. The expression data for the cell lines
are displayed to the left of the main panel in Figure 1.
|
Several features of the gene expression patterns are evident in Figure 1. First, based solely on their gene expression patterns, the clinical samples could be divided into two major clusters, one representing HCC samples, and the other, with a few exceptions, representing nontumor liver tissues. Second, expression patterns varied significantly among the HCC and nontumor liver samples. Third, samples from HBV-infected, hepatitis C virus-infected, and noninfected individuals were interspersed in the HCC branch.
Close-up views of clusters of genes whose expression covaries in
this set of samples are shown in Figure
2. One cluster of genes was highly
expressed in HCC samples compared with nontumor liver tissues. It
includes the "proliferation cluster" (Figure 2A), comprised of
genes whose functions are required for cell cycle progression and whose
expression levels correlate with cellular proliferation rates. Most of
the genes in this cluster are specifically expressed in G2/M phase (Cho
et al., 2001
). As expected, liver cell lines, continuously
proliferating in culture, also expressed the genes in this cluster at
high levels. Genes encoding ribosomal proteins were also relatively
highly expressed in HCC, an expression pattern characteristically
observed in growing cells. Other genes not known to be related to cell
proliferation or translation also showed consistently elevated
expression in HCC. These genes are implicated in a variety of cellular
process, including cell signaling, transcriptional regulation, RNA
splicing, protein degradation, and cell adhesion. The functional
significance of their elevated expression in HCC remains to be
elucidated.
|
Among the genes that were expressed at lower levels in HCC than in nontumor liver tissues, most seemed to be genes specifically expressed in differentiated hepatocytes (Figure 2B), including genes encoding liver-specific metabolic enzymes and many plasma proteins, including clotting factors, apolipoproteins, and complement proteins. When expanded in vitro, HCC cell lines have been found to lose expression of most "liver-specific markers." These data confirm that many of the characteristic molecular features of normal hepatocytes are clearly also deficient in the tumor themselves.
Both normal liver and liver tumors are complex tissues composed of diverse specialized cells. Distinct patterns of gene expression seemed to provide molecular signatures of several specific cell types. Expression of two clusters of genes associated with T and B lymphocytes, respectively, presumably reflects lymphocytic infiltration into liver tissues (Figure 2, C and D). In nontumor liver tissues, their expression correlated with viral infection, perhaps reflecting the chronic inflammatory response to the infection.
The expression patterns of two distinct clusters of genes seem to
reflect variation in the density and composition of stromal cells
(Figure 2, E and F). Several of the genes in the second group,
including LTBP2, CSPG2, and TIMP1, have been shown to be expressed in
activated stellate cells in response to liver injury (Gressner et
al., 1994
). Variation in expression of this cluster of genes may
therefore reflect variation in the distribution of activated stellate
cells in the tissues.
A cluster that included several genes typically expressed in endothelial cells, including CD34, RGS5, and THY1, was expressed at a higher level in HCC than in nontumor liver tissues (Figure 2G). CD34 is expressed in endothelial cells in veins and arteries but not in the endothelial cells of the sinusoids in nontumor liver. However, it is strongly expressed in the endothelial cells that line the sinusoid-like vessels in the HCC samples (Figure 2I), presumably reflecting disruption in HCC of the molecular program that normally regulates blood vessel morphogenesis in the liver. A second cluster of genes characteristically expressed in endothelial cells, including VWF, hevin, and VE-cadherin (Figure 2H), showed variable expression among the tissue samples and no systematic difference in expression between HCC and nontumor liver tissues. These two groups of genes may therefore represent two distinct types of endothelial-like cells in liver.
Clonal and Genotypic Variation in Gene Expression Patterns in HCC Samples
Previous work has suggested that the gene expression pattern of a
tumor can provide a distinctive molecular portrait recognizable in
successive samples over time and in metastases (Perou et
al., 2000
). How distinctive and consistent are the gene expression patterns in individual hepatocellular carcinomas? We investigated whether samples from multiple sites in a single HCC tumor, or multiple
separate tumor nodules in one patient, would share a recognizable gene
expression signature. We analyzed 102 HCC samples from 82 patients by
hierarchical clustering based on the overall similarity in their
pattern of expression of 2640 genes (represented by 3271 cDNA clones)
(Figure 3A). With a few instructive
exceptions, all the tumors samples from each patient clustered
together.
|
To further examine the relationships among multiple tumor samples from individual patients, we calculated the pairwise r for all pairs of samples and displayed the results in Figure 3B. For SF1, SF34, SF35, and HK62, each primary tumor was sampled multiple times. For each of these tumors, the pattern of gene expression in a given tumor sample was more highly correlated with the pattern seen in the other samples from the sample patient than with any of the other tumors we analyzed. Every tumor therefore had a distinctive and characteristic gene expression pattern, recognizable in all samples taken from different areas of the same tumor.
Multiple discrete tumor masses were obtained from six patients. In three of these patients, HK63, HK64, and HK66, the multiple tumors shared a distinctive gene expression pattern. In the three other patients, HK65, HK67, and HK85, the expression patterns varied between tumor nodules, and the difference provides new insights into the sources of variation in the molecular and biological characteristics of cancers.
Recent studies have shown that the gene expression patterns in samples
of a given tumor taken at different times or from different sites are
typically much more similar to one another than are the expression
patterns observed in tumors of the same type in different patients
(Perou et al., 2000
). Do the distinctive expression patterns
characteristic of each tumor reflect the individuality of the tumor, or
are they determined by the patient in whom the tumor arose? Analysis of
the multifocal hepacellular carcinomas provides an opportunity to
address this important question.
The expression patterns observed in the two tumor nodules from patient HK85 were not significantly more similar than those of an arbitrary pair of tumors from different patients. These two tumor nodules were each 2 cm in diameter and were separated by a distance of 7 cm. Southern analysis of the HBV integration sites showed that T1 and T2 had distinct integration patterns (see supplementary information), strongly suggesting that they were clonally independent tumors.
The tumor nodules from patient HK65 were immediately adjacent, but
grossly separated foci. Each tumor mass was ~2 cm in diameter. The
gene expression patterns observed in tumor nodules HK65-T2 and HK65-T4
were more similar to each other than either was to the pattern observed
in HK65-T1. The gene expression patterns in the tumor nodules in this
patient showed an intriguing relationship to p53 activity. In normal
cells, p53 is so rare that the protein usually cannot be detected by
standard immunohistochemical staining. Positive p53 staining generally
indicates a mutant form of p53 gene in HCC tissues (Hsu et
al., 1993
), probably because the mutated p53 protein is more
stable and accumulates in the nuclei. p53 was undetectable by
immunohistochemical staining in T2 and T4, but it was readily detected
in the nuclei of tumor cells in T1 (Figure 3C). To investigate the
clonality of these tumor nodules, we performed Southern analysis of the
HBV integration site on T1 and T2 (see supplementary information). The
HBV integration sites in these tumors seemed indistinguishable,
suggesting they arose from the same clone. We used microarray CGH to
characterize the patterns of chromosomal amplifications and deletions
in T1 and T2 (see supplementary information). Although the chromosomal changes in T1 seemed, by this assay, generally similar to those seen in
T2, T1 showed some distinct patterns, including partial or complete
loss of a copy of chromosomes 5q, 9p, 12, and 22. All these data
suggest that despite their common clonal origin, the genome of T1 is
distinctly different from that of T2 and T4, presumably accounting for
the differences in gene expression pattern.
In patient HK67, T1 was the main tumor mass, measuring 8 cm in
diameter. T2 and T3, measuring 1 and 3 cm, respectively, were satellite
nodules in a different liver lobe. expression patterns of T2 and T3
were remarkably similar, but only distantly related to the pattern
observed in T1. Although p53 was uniformly detectable by
immunohistochemistry in the nuclei of tumors cells in T2 and T3, the
immunostaining pattern observed in T1 was heterogeneous. In most areas,
p53 staining was undetectable, but in some patches of this tumor, p53
staining was readily detected in >50% of the tumor cell nuclei
(Figure 3D). Genes associated with proliferation were expressed at
significantly higher levels in T2 and T3 than in T1. Array CGH analysis
revealed very similar patterns of chromosomal amplifications and
deletions in T1 and T2, including rare chromosomal abnormalities (Wong
et al., 1999
; Shiraishi et al., 2001
) such as
amplification of 19q, and deletion of 15q and the centromere region of
22 (see supplementary information), suggesting a common clonal origin.
However, T2 was distinguished from T1 by an additional deletion of
chromosome 13. The data suggest that at least some of the tumor cells
of T1 are genotypically unstable, resulting in genotypic heterogeneity
among the cells in this tumor. In view of their smaller size, faster
proliferation, and homogeneity with respect to p53 staining, T2 and T3
are probably subclones derived from T1. The p53 mutation and other
genetic changes apparently provided a growth, survival, or migration
advantage that enabled these clones to outgrow and metastasize.
Taken together, these results suggest that each independently arising tumor is distinguished from other tumors of the same pathological type, whether they arise in the same patient or different patients, by a distinctive gene expression program that reflects the cell of origin and the unique sequence of genetic events. Moreover, multiple clonally related tumor samples in the same patients can show different gene expression patterns due to divergent histories of mutations or chromosomal alterations.
Correlation between p53 Accumulation and Cell Proliferation
Mutations in the p53 gene are a common finding in HCC and may play
a key role in pathogenesis. To investigate the relationship between p53
mutations and the gene expression program in HCC, 59 HCC specimens were
examined by immunohistochemical staining for p53 protein. Positive p53
staining, which has been noted to correlate with p53 mutation or
inflammation in HCC (Hsu et al., 1993
), was found in 23 of
the tumors analyzed. We found no apparent correlation between p53
staining and histological evidence of inflammation in our series.
Among the 59 samples we analyzed, we found characteristic differences
in gene expression patterns between the tumors with positive p53
staining and those with negative p53 staining. We identified 121 genes
whose expression level was correlated with p53 staining, with p < 0.001 by two-sample Welch t statistics (Figure
4). Of these 121 genes, 86 were more
highly expressed in tumors with positive immunostaining for p53. Most
of these 86 genes belonged to the proliferation cluster, i.e., their
expression was strongly associated with proliferation, suggesting that
mutation of p53 might be a key pathogenetic event leading to
accelerated cell proliferation during HCC tumorgenesis.
|
Most of the 35 genes that were characteristically expressed at lower
levels in the HCC samples with positive p53 staining are noteworthy for
their specific expression in differentiated hepatocytes, presumably
reflecting a tendency for tumors cells with p53 mutations to be poorly
differentiated (Caruso and Valentini, 1999
). Interestingly, one of
these genes, MST, also called hepatocyte growth factor-like protein,
has been reported to be induced by p53 expression (Zhao et
al., 2000
), raising the possibility of a role for this putative
growth factor in p53-dependent regulation of hepatocyte differentiation.
Vascular Invasion and Gene Expression Pattern in HCC
Vascular invasion seems to have an important role in tumor spread
and metastasis. All tumor samples were classified by histopathological evaluation as either positive or negative for vascular invasion. We
identified 91 genes whose expression levels were significantly correlated with the presence or absence of vascular invasion by two-sample Welch t statistics (p < 0.001) (Figure
5).
|
Sixty-one of these genes were expressed at higher levels in tumors with
vascular invasion than in tumors without vascular invasion. Most of
these genes had functions and expression patterns associated with cell
proliferation. One of the few genes in this set that seems to be
unrelated to cell proliferation encodes matrix metalloproteinase (MMP)
14. MMP family members are involved in the breakdown of extracellular
matrix and may play important roles in invasion and metastasis (Liotta
et al., 1980
; Arii et al., 1996
; Hayasaka
et al., 1996
). MMP14 may have a direct role in activation of
MMP2 (Sato et al., 1994
), which in turn has been shown to be
related to an invasive phenotype and poor prognosis in HCC (Murakami
et al., 1999
). The association of MMP14 expression with
vascular invasion highlights the possible importance of these MMPs in
the progression of HCC and underscores their potential as therapeutic targets.
Most of the genes that were expressed at lower levels in the tumors
with vascular invasion were "liver specific," consistent with the
classical pathological observation that poorly differentiated HCC
tumors tend to be more aggressive and invasive (Ng et al., 1995
). One of the few genes in this group that did not belong to the
liver-specific cluster encodes the metalloprotease ADAMTS1, which was
recently shown to inhibit endothelial cell proliferation and to have
antiangiogenic activity (Vazquez et al., 1999
). Although vascular invasion and angiogenesis have traditionally been viewed as
independent properties of a tumor, a recent study has suggested an
association between vascular invasion and intratumoral angiogenesis (Maehara et al., 2000
). The function and regulation of
ADAMTS1, and its possible role in suppressing vascular invasion and
angiogenesis, warrant further investigation.
Expression Patterns Distinguish Cancers Metastatic to Liver from Primary HCC
Many tumors, particularly those arising in the gastrointestinal
tract, have a propensity to metastasize to the liver. We examined several metastatic lesions in the liver. The expression patterns of 10 randomly selected HCC samples and 10 liver metastases of other cancers
were analyzed by hierarchical clustering as shown in Figure
6. The HCC samples and the metastatic
cancers clustered into two distinct groups, based on differences in
their patterns of gene expression. Although some of the HCC samples
were poorly differentiated and expressed the genes of the
liver-specific cluster at very low levels compared with either normal
liver or well-differentiated HCC, the genes of the liver-specific
cluster were consistently expressed at higher levels in HCC than in
tumors of nonliver origin. Metastatic cancers originating from the same
tissue typically clustered together, expressing genes characteristic of
the cell type of origin. For example, the four samples of metastatic
colon adenocarcinoma clustered together, distinguished in part by their abundant expression of the keratin 17, keratin 19, and mucin 1 genes.
In contrast, a metastatic carcinoid tumor from the colon expressed
genes commonly associated with neurons and neuroendocrine cells,
including syntaxin 1A and syntaxin binding protein 1. The sample
labeled HK17, diagnosed as undifferentiated adenocarcinoma, expressed a
distinctive set of genes. Due in part to the small number and limited
diversity of the non-HCC tumors in this study we cannot pinpoint the
site from which this tumor arose. We are optimistic, however, that
systematic comparison of the gene expression pattern in a metastatic
tumor of uncertain origin with the expression patterns observed in a
large, diverse sample of tumors and normal tissues will allow reliable
recognition of the primary tumor of origin.
|
| |
DISCUSSION |
|---|
|
|
|---|
The molecular pathogenesis of HCC is still poorly understood, and
its clinical course can vary widely. Systematic analysis of global gene
expression programs in human cancers can lead to new insights into
pathogenetic mechanisms and improved prediction of clinical behavior
(Golub et al., 1999
; Alizadeh et al., 2000
; Perou
et al., 2000
). A recent report analyzed gene expression patterns in 20 HCC samples (Okabe et al., 2001
), by directly
comparing tumor to nontumor liver tissue from the same patient. The
studies noted the elevated expression of proliferation-associated genes in the tumors, and suggested that expression of specific genes could be
associated with the viral etiology of the tumor, vascular invasion, and
other features. The interpretation of these results was complicated,
however, by the fact that the gene expression patterns in the nontumor
liver samples from different patients can vary significantly, affected
by the viral infection and degree of cirrhosis (Figure 1). Thus, the
tumor-specific variation in the expression patterns could not be
distinguished from variation due to differences in the corresponding
nontumor liver samples.
In this study, we used a common reference RNA sample as an internal standard for measurement of expression in each clinical specimen, allowing systematic comparisons to be made among all of our tumor and nontumor tissues and cell lines. HCC and nontumor liver samples were readily divided into two separate major branches when these tissues were hierarchically clustered based on their gene expression patterns, reflecting the consistent differences between the gene expression program in HCC and nontumor liver tissues. Of the 3180 genes that showed the greatest variation in expression among all the samples we studied (Figure 1), ~1640 genes were differentially expressed in HCC vs. nontumor liver samples (p < 0.01 by Student's t test with Bonferroni correction; see supplementary information).
Primary HCC was readily distinguished from tumors metastatic to liver based on differences in global gene expression patterns. Metastatic tumors from the same primary site shared distinctive gene expression patterns that seemed to be related to their normal cellular progenitor. Metastatic tumors of unknown primary origin are not rare. Classification of these tumors according to the primary tumor of origin has important implications for treatment. Our preliminary results provide encouraging support for the hypothesis that tumors of unknown primary could be identified by comparing their gene expression patterns with the profiles of diverse malignant and normal tissues.
As observed for breast cancers (Perou et al., 2000
),
lymphomas (Alizadeh et al., 2000
), and other cancers (our
unpublished data), the gene expression pattern of each HCC seems
to provide a distinctive molecular portrait of that tumor, several
features of which are statistically associated with specific phenotypic features of the tumors. Multiple tumor samples from the same patient typically share recognizable and distinctive features in their gene
expression patterns. An important question raised by this recurrent
observation is whether the differences in gene expression patterns
reflect the individuality of the tumors or the patients in whom the
tumors arise. The results of this study provide a partial answer. In a
few cases, separate tumors from a single patient showed dramatic
differences in their gene expression patterns. We found that the
differences are likely due either to independent clonal origins of
separate HCCs in the same patient (HK85), or to divergent genotypic
evolution of clonally related tumors (HK65 and HK67). Therefore, the
differences that distinguish the gene expression programs of individual
tumors of the same histological type seem primarily to arise during the
development and progression of the tumors, rather than reflecting
underlying differences between the patients in whom the tumors arose.
Extensive variation in histology and cell morphology is a frequent feature of cancer. The microscopic heterogeneity in p53 protein levels observed in one of the tumors were analyzed, HK67, provides an informative example (Figure 3D). The RNA samples were analyzed in this study were isolated from macroscopic tumor samples ~1 cm3 in size, a scale too large to allow resolution of the differences in gene expression to accompany the differences in p53 activity (and presumably other genotypic variation) represented in this heterogeneous tumor sample. However, the differences in the expression patterns observed between the largest tumor mass in patient HK67, tumor T1, and tumor nodules T2 and T3, presumed to be intrahepatic metastases from T1, support the hypothesis that the cellular heterogeneity observed at the histological level is accompanied by corresponding heterogeneity in the gene expression patterns. Clearly, this important phenomenon warrants further study by using methods such as laser-capture microdissection and immunhistochemistry, which can allow molecular variation at the level of single cells to be characterized in greater detail.
Among the genes that were characteristically highly expressed in HCC,
those whose products are membrane associated or secreted are of
particular interest for their potential as therapeutic targets or as
serological markers for early detection.
-Fetoprotein has been
widely used as the serum marker for HCC diagnosis and follow-up.
However, it is elevated in only 50% of HCC (Johnson, 2001
) (Figure 1).
Additional, and better, serological markers are clearly needed. In this
study, we were able to identify hundreds of genes whose expression was
more consistently elevated in HCC than was
-fetoprotein (see
supplementary information). Using a DNA microarray method for
identification of membrane-associated transcripts (Diehn et
al., 2000
) and sequence analysis for transmembrane domain or
signal peptides (Kyte and Doolittle, 1982
; Nielsen et al.,
1997
), we were able to distinguish a subset of these genes whose
products are likely to be either membrane bound or secreted (Diehn,
unpublished data). By raising antibodies against the products of these
genes, we hope to identify new serum markers for detection and
diagnosis of HCC, and perhaps new candidate targets for treatment.
Supplementary information is available on the authors' World-Wide Web site (http://genome-www.stanford.edu/hcc).
| |
ACKNOWLEDGMENTS |
|---|
We thank the members of the Stanford Microarray Facility and Stanford Microarray Database, especially Mike Fero, Gavin Sherlock and Tina Hernandez-Boussard. We thank B. Strausberg at NCI for CGAP clones. We also thank the members of the Asian Liver Center at Stanford, especially Wijan Prapong and Ann Vu-Nguyen. We are grateful for the members of the Brown and Botstein laboratories for helpful discussions and comments on the manuscript. Research at Stanford was supported by grants from the National Cancer Institute to P.O.B and D.B., by a grant from the H. M. Lui Foundation to S.S., and by the Howard Hughes Medical Institute. The work of S.T.C. and S.T.F. was supported in part by a grant from the Sun Chieh-Yeh Research Foundation for Hepatobiliary and Pancreatic Surgery, HKU. X.C. is a Howard Hughes fellow of the Life Science Research Foundation. P.O.B. is an Associate Investigator of the Howard Hughes Medical Institute.
| |
FOOTNOTES |
|---|
** Corresponding authors. E-mail addresses: pbrown{at}cmgm.stanford.edu or botstein{at}genome.stanford.edu.
X.C. and S.T.C. contributed equally to this work.
Article published online ahead of print. Mol. Biol. Cell 10.1091/mbc.02-02-0023. Article and publication date are at www.molbiolcell.org/cgi/doi/10.1091/mbc.02-02-0023.
| |
ABBREVIATIONS |
|---|
Abbreviations used: HCC, hepatocellular carcinoma; p53, tumor protein p53 (Li-Fraumeni syndrome).
| |
REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
M. Condomines, D. Hose, T. Reme, G. Requirand, M. Hundemer, M. Schoenhals, H. Goldschmidt, and B. Klein Gene Expression Profiling and Real-Time PCR Analyses Identify Novel Potential Cancer-Testis Antigens in Multiple Myeloma J. Immunol., July 15, 2009; 183(2): 832 - 840. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yang, H. Li, Z. Zhou, W.-H. Wang, A. Deng, O. Andrisani, and X. Liu Plk1-mediated Phosphorylation of Topors Regulates p53 Stability J. Biol. Chem., July 10, 2009; 284(28): 18588 - 18592. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Nitin, W. J. Rhee, and G. Bao Translation inhibition reveals interaction of 2'-deoxy and 2'-O-methyl molecular beacons with mRNA targets in living cells Nucleic Acids Res., June 15, 2009; (2009) gkp517v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, F. Yin, Y. Du, W. Du, B. Chen, Y. Zhang, K. Wu, J. Ding, J. Liu, and D. Fan MAD2 as a Key Component of Mitotic Checkpoint: A Probable Prognostic Factor for Gastric Cancer Am J Clin Pathol, June 1, 2009; 131(6): 793 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lausted, Z. Hu, and L. Hood Quantitative Serum Proteomics from Surface Plasmon Resonance Imaging Mol. Cell. Proteomics, December 1, 2008; 7(12): 2464 - 2474. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Rakotomalala, L. Studach, W.-H. Wang, G. Gregori, R. L. Hullinger, and O. Andrisani Hepatitis B Virus X Protein Increases the Cdt1-to-Geminin Ratio Inducing DNA Re-replication and Polyploidy J. Biol. Chem., October 17, 2008; 283(42): 28729 - 28740. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zheng, S. E. Morgan-Lappe, J. Yang, K. M. Bockbrader, D. Pamarthy, D. Thomas, S. W. Fesik, and Y. Sun Growth Inhibition and Radiosensitization of Glioblastoma and Lung Cancer Cells by Small Interfering RNA Silencing of Tumor Necrosis Factor Receptor-Associated Factor 2 Cancer Res., September 15, 2008; 68(18): 7570 - 7578. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zhang, C. Yao, Z. Guo, J. Zou, L. Zhang, H. Xiao, D. Wang, D. Yang, X. Gong, J. Zhu, et al. Apparently low reproducibility of true differential expression discoveries in microarray studies Bioinformatics, September 15, 2008; 24(18): 2057 - 2063. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Y. Chiang, A. Villanueva, Y. Hoshida, J. Peix, P. Newell, B. Minguez, A. C. LeBlanc, D. J. Donovan, S. N. Thung, M. Sole, et al. Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma Cancer Res., August 15, 2008; 68(16): 6779 - 6788. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Montanaro, D. Trere, and M. Derenzini Nucleolus, Ribosomes, and Cancer Am. J. Pathol., August 1, 2008; 173(2): 301 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Liu, L. Wang, S. Zhang, J. Lin, S. Zhang, M. A. Feitelson, H. Gao, and M. Zhu Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses Carcinogenesis, June 1, 2008; 29(6): 1207 - 1214. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Acevedo, M. Bieda, R. Green, and P. J. Farnham Analysis of the Mechanisms Mediating Tumor-Specific Changes in Gene Expression in Human Liver Tumors Cancer Res., April 15, 2008; 68(8): 2641 - 2651. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. G. Yulug and B. Gur-Dedeoglu Functional genomics in translational cancer research: focus on breast cancer Brief Funct Genomic Proteomic, March 7, 2008; (2008) eln009v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Yang, Y. Li, H. Xiao, Q. Liu, M. Zhang, J. Zhu, W. Ma, C. Yao, J. Wang, D. Wang, et al. Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories Bioinformatics, January 15, 2008; 24(2): 265 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Katzenellenbogen, L. Mizrahi, O. Pappo, N. Klopstock, D. Olam, J. Jacob-Hirsch, N. Amariglio, G. Rechavi, E. Domany, E. Galun, et al. Molecular Mechanisms of Liver Carcinogenesis in the Mdr2-Knockout Mice Mol. Cancer Res., November 1, 2007; 5(11): 1159 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, J. Huang, N. Yang, J. Greshock, S. Liang, K. Hasegawa, A. Giannakakis, N. Poulos, A. O'Brien-Jenkins, D. Katsaros, et al. Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer Clin. Cancer Res., September 15, 2007; 13(18): 5314 - 5321. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Wong, H. Haack, J. L. Kissil, M. Barry, R. T. Bronson, S. S. Shen, C. A. Whittaker, D. Crowley, and R. O. Hynes Protein 4.1B suppresses prostate cancer progression and metastasis PNAS, July 31, 2007; 104(31): 12784 - 12789. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nicolau, R. Tibshirani, A.-L. Borresen-Dale, and S. S. Jeffrey Disease-specific genomic analysis: identifying the signature of pathologic biology Bioinformatics, April 15, 2007; 23(8): 957 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Podar, M. S. Raab, G. Tonon, M. Sattler, D. Barila, J. Zhang, Y.-T. Tai, H. Yasui, N. Raje, R. A. DePinho, et al. Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma Cancer Res., February 15, 2007; 67(4): 1680 - 1688. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Qiu, Z. J. Wang, K. J. R. Liu, Z.-Z. Hu, and C. H. Wu Dependence network modeling for biomarker identification Bioinformatics, January 15, 2007; 23(2): 198 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. S. Tompkins, J. Hagen, A. A. Frazier, T. Lushnikova, M. P. Fitzgerald, A. di Tommaso, V. Ladeveze, F. E. Domann, C. M. Eischen, and D. E. Quelle A Novel Nuclear Interactor of ARF and MDM2 (NIAM) That Maintains Chromosomal Stability J. Biol. Chem., January 12, 2007; 282(2): 1322 - 1333. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Pelham, L. Rodgers, I. Hall, R. Lucito, K. C. Q. Nguyen, N. Navin, J. Hicks, D. Mu, S. Powers, M. Wigler, et al. Identification of alterations in DNA copy number in host stromal cells during tumor progression PNAS, December 26, 2006; 103(52): 19848 - 19853. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-C. Ho, J.-J. Lin, C.-N. Chen, C.-C. Chen, H. Lee, C.-Y. Yang, Y.-H. Ni, K.-J. Chang, H.-C. Hsu, F.-J. Hsieh, et al. A Gene Expression Profile for Vascular Invasion can Predict the Recurrence After Resection of Hepatocellular Carcinoma: a Microarray Approach Ann. Surg. Oncol., November 1, 2006; 13(11): 1474 - 1484. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yu, J. Lin, D. J. Zack, and J. Qian Computational analysis of tissue-specific combinatorial gene regulation: predicting interaction between transcription factors in human tissues Nucleic Acids Res., October 18, 2006; 34(17): 4925 - 4936. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Z. Ring, R. S. Seitz, R. Beck, W. J. Shasteen, S. M. Tarr, M. C.U. Cheang, B. J. Yoder, G. T. Budd, T. O. Nielsen, D. G. Hicks, et al. Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor-Positive Breast Cancer J. Clin. Oncol., July 1, 2006; 24(19): 3039 - 3047. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Mann, M. G. Backlund, F. G. Buchanan, T. Daikoku, V. R. Holla, D. W. Rosenberg, S. K. Dey, and R. N. DuBois Repression of Prostaglandin Dehydrogenase by Epidermal Growth Factor and Snail Increases Prostaglandin E2 and Promotes Cancer Progression. Cancer Res., July 1, 2006; 66(13): 6649 - 6656. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ito, S.-i. Funahashi, N. Yamauchi, J. Shibahara, Y. Midorikawa, S. Kawai, Y. Kinoshita, A. Watanabe, Y. Hippo, T. Ohtomo, et al. Identification of ROBO1 as a Novel Hepatocellular Carcinoma Antigen and a Potential Therapeutic and Diagnostic Target. Clin. Cancer Res., June 1, 2006; 12(11): 3257 - 3264. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fahling, R. Mrowka, A. Steege, P. Martinka, P. B. Persson, and B. J. Thiele Heterogeneous Nuclear Ribonucleoprotein-A2/B1 Modulate Collagen Prolyl 4-Hydroxylase, {alpha} (I) mRNA Stability J. Biol. Chem., April 7, 2006; 281(14): 9279 - 9286. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Smith, G. Oxford, Z. Wu, M. D. Nitz, M. Conaway, H. F. Frierson, G. Hampton, and D. Theodorescu The Metastasis-Associated Gene CD24 Is Regulated by Ral GTPase and Is a Mediator of Cell Proliferation and Survival in Human Cancer Cancer Res., February 15, 2006; 66(4): 1917 - 1922. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Fong, M.-S. Chua, A. B. McKie, S. H. M. Ling, V. Mason, R. Li, P. Yusoff, T. L. Lo, H. Y. Leung, S. K.S. So, et al. Sprouty 2, an Inhibitor of Mitogen-Activated Protein Kinase Signaling, Is Down-Regulated in Hepatocellular Carcinoma Cancer Res., February 15, 2006; 66(4): 2048 - 2058. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zerbini, M. Pilli, A. Penna, G. Pelosi, C. Schianchi, A. Molinari, S. Schivazappa, C. Zibera, F. F. Fagnoni, C. Ferrari, et al. Radiofrequency Thermal Ablation of Hepatocellular Carcinoma Liver Nodules Can Activate and Enhance Tumor-Specific T-Cell Responses Cancer Res., January 15, 2006; 66(2): 1139 - 1146. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, H. Zhao, Q. Xu, W. Jin, C. Liu, H. Zhang, Z. Huang, X. Zhang, Y. Zhang, D. Xin, et al. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma Nucleic Acids Res., January 1, 2006; 34(suppl_1): D607 - D612. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Choi, U. Yu, O. J. Yoo, and S. Kim Differential coexpression analysis using microarray data and its application to human cancer Bioinformatics, December 15, 2005; 21(24): 4348 - 4355. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Patil, I. Gutgemann, J. Zhang, C. Ho, S.-T. Cheung, D. Ginzinger, R. Li, K. J. Dykema, S. So, S.-T. Fan, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma Carcinogenesis, December 1, 2005; 26(12): 2050 - 2057. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Jornsten, H.-Y. Wang, W. J. Welsh, and M. Ouyang DNA microarray data imputation and significance analysis of differential expression Bioinformatics, November 15, 2005; 21(22): 4155 - 4161. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hu and R. A. Shivdasani Overlapping Gene Expression in Fetal Mouse Intestine Development and Human Colorectal Cancer Cancer Res., October 1, 2005; 65(19): 8715 - 8722. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. D. Miller, J. Smeds, J. George, V. B. Vega, L. Vergara, A. Ploner, Y. Pawitan, P. Hall, S. Klaar, E. T. Liu, et al. From The Cover: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival PNAS, September 20, 2005; 102(38): 13550 - 13555. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lu, P.-Y. Liu, P. Xiao, and H.-W. Deng Hotelling's T2 multivariate profiling for detecting differential expression in microarrays Bioinformatics, July 15, 2005; 21(14): 3105 - 3113. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Alpy and C. Tomasetto Give lipids a START: the StAR-related lipid transfer (START) domain in mammals J. Cell Sci., July 1, 2005; 118(13): 2791 - 2801. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Lee, J. W. Grisham, and S. S. Thorgeirsson Comparative functional genomics for identifying models of human cancer Carcinogenesis, June 1, 2005; 26(6): 1013 - 1020. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Gilad, S. A. Rifkin, P. Bertone, M. Gerstein, and K. P. White Multi-species microarrays reveal the effect of sequence divergence on gene expression profiles Genome Res., May 1, 2005; 15(5): 674 - 680. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liang, M. Diehn, N. Watson, A. W. Bollen, K. D. Aldape, M. K. Nicholas, K. R. Lamborn, M. S. Berger, D. Botstein, P. O. Brown, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme PNAS, April 19, 2005; 102(16): 5814 - 5819. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bertucci, P. Finetti, J. Rougemont, E. Charafe-Jauffret, N. Cervera, C. Tarpin, C. Nguyen, L. Xerri, R. Houlgatte, J. Jacquemier, et al. Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast Cancer Cancer Res., March 15, 2005; 65(6): 2170 - 2178. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Cheung, K. L. Leung, Y. C. Ip, X. Chen, D. Y. Fong, I. O. Ng, S. T. Fan, and S. So Claudin-10 Expression Level is Associated with Recurrence of Primary Hepatocellular Carcinoma Clin. Cancer Res., January 15, 2005; 11(2): 551 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. TONON, C. BRENNAN, A. PROTOPOPOV, G. MAULIK, B. FENG, Y. ZHANG, D.B. KHATRY, M.J. YOU, A.J. AGUIRRE, E.S. MARTIN, et al. Common and Contrasting Genomic Profiles among the Major Human Lung Cancer Subtypes Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 11 - 24. [Abstract] [PDF] |
||||
![]() |
S. T. Cheung, S. Y. Wong, K. L. Leung, X. Chen, S. So, I. O. Ng, and S. T. Fan Granulin-Epithelin Precursor Overexpression Promotes Growth and Invasion of Hepatocellular Carcinoma Clin. Cancer Res., November 15, 2004; 10(22): 7629 - 7636. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-W. L. Hann, J. Lee, A. Bussard, C. Liu, Y. R. Jin, K. Guha, M. M. Clayton, K. Ardlie, M. J. Pellini, and M. A. Feitelson Preneoplastic Markers of Hepatitis B Virus-Associated Hepatocellular Carcinoma Cancer Res., October 15, 2004; 64(20): 7329 - 7335. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Breuhahn, S. Vreden, R. Haddad, S. Beckebaum, D. Stippel, P. Flemming, T. Nussbaum, W. H. Caselmann, B. B. Haab, and P. Schirmacher Molecular Profiling of Human Hepatocellular Carcinoma Defines Mutually Exclusive Interferon Regulation and Insulin-Like Growth Factor II Overexpression Cancer Res., September 1, 2004; 64(17): 6058 - 6064. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, and A. M. Chinnaiyan Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression PNAS, June 22, 2004; 101(25): 9309 - 9314. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. K. Lee, A. K. Hsu, J. Sajdak, J. Qin, and P. Pavlidis Coexpression Analysis of Human Genes Across Many Microarray Data Sets Genome Res., June 1, 2004; 14(6): 1085 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Rubin, S. Varambally, R. Beroukhim, S. A. Tomlins, D. R. Rhodes, P. L. Paris, M. D. Hofer, M. Storz-Schweizer, R. Kuefer, J. A. Fletcher, et al. Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer Cancer Res., June 1, 2004; 64(11): 3814 - 3822. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hippo, K. Watanabe, A. Watanabe, Y. Midorikawa, S. Yamamoto, S. Ihara, S. Tokita, H. Iwanari, Y. Ito, K. Nakano, et al. Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma Cancer Res., April 1, 2004; 64(7): 2418 - 2423. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets PNAS, July 8, 2003; 100(14): 8418 - 8423. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Kim and X. W. Wang Gene expression profiling of preneoplastic liver disease and liver cancer: a new era for improved early detection and treatment of these deadly diseases? Carcinogenesis, March 1, 2003; 24(3): 363 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Moriyama, Y. Hoshida, M. Otsuka, S. Nishimura, N. Kato, T. Goto, H. Taniguchi, Y. Shiratori, N. Seki, and M. Omata Relevance Network between Chemosensitivity and Transcriptome in Human Hepatoma Cells Mol. Cancer Ther., February 1, 2003; 2(2): 199 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. BOTSTEIN Genomic Perspective and Cancer Cold Spring Harb Symp Quant Biol, January 1, 2003; 68(0): 417 - 424. [Abstract] [PDF] |
||||
![]() |
S. Y. Leung, X. Chen, K. M. Chu, S. T. Yuen, J. Mathy, J. Ji, A. S. Y. Chan, R. Li, S. Law, O. G. Troyanskaya, et al. Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis PNAS, December 10, 2002; 99(25): 16203 - 16208. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||